Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/ijms21155238 http://scihub22266oqcxt.onion/10.3390/ijms21155238 32718086!7432115!32718086     free     free     free       Int+J+Mol+Sci 2020 ; 21 (15): ä Nephropedia Template TP {{tp|p=32718086|t=2020. Interleukin-6 in Rheumatoid Arthritis |pdf=|usr=}}{{32718086}} gab.com Text Interleukin-6 in Rheumatoid Arthritis JO: Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32718086 #FOAvip The role of interleukin (IL)-6 in health and disease has been under a lot of scrutiny in recent years, particularly during the recent COVID-19 pandemic. The inflammatory pathways in which IL-6 is involved are also partly responsible of the development and progression of rheumatoid arthritis (RA), opening interesting perspectives in terms of therapy. Anti-IL-6 drugs are being used with variable degrees of success in other diseases and are being tested in RA. Results have been encouraging, particularly when anti-IL-6 has been used with other drugs, such as metothrexate (MTX). In this review we discuss the main immunologic aspects that make anti-IL-6 a good candidate in RA, but despite the main therapeutic options available to target IL-6, no gold standard treatment has been established so far. Twit Text FOAVip Interleukin-6 in Rheumatoid Arthritis ????Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32718086 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32718086 #FOAvip English Wikipedia <ref>{{Cite pmid|32718086}}</ref> Interleukin-6 in Rheumatoid Arthritis #MMPMID32718086 Pandolfi F; Franza L; Carusi V; Altamura S; Andriollo G; Nucera E Int J Mol Sci 2020[Jul]; 21 (15): ä PMID32718086show ga The role of interleukin (IL)-6 in health and disease has been under a lot of scrutiny in recent years, particularly during the recent COVID-19 pandemic. The inflammatory pathways in which IL-6 is involved are also partly responsible of the development and progression of rheumatoid arthritis (RA), opening interesting perspectives in terms of therapy. Anti-IL-6 drugs are being used with variable degrees of success in other diseases and are being tested in RA. Results have been encouraging, particularly when anti-IL-6 has been used with other drugs, such as metothrexate (MTX). In this review we discuss the main immunologic aspects that make anti-IL-6 a good candidate in RA, but despite the main therapeutic options available to target IL-6, no gold standard treatment has been established so far. |Antibodies, Monoclonal/pharmacology/therapeutic use[MESH] |Arthritis, Rheumatoid/drug therapy/*immunology[MESH] |Disease Progression[MESH] |Humans[MESH] |Interleukin-6/antagonists & inhibitors/*metabolism[MESH] |Molecular Targeted Therapy[MESH]Interleukin-6 in Rheumatoid Arthritis (epmc).pdf DeepDyve Pubget Overpricing